康龍化成(03759.HK)出資參與的私募股權投資基金完成備案登記
格隆匯9月10日丨康龍化成(03759.HK)公吿,康龍化成(北京)新藥技術股份有限公司(以下簡稱“公司”)已於2021年3月26日召開第二屆董事會第九次會議和第二屆監事會第六次會議審議通過了《關於參與私募股權投資基金暨關聯交易的議案》,同意公司作為有限合夥人以自有資金認繳出資26,000萬元人民幣,參與關聯方康君投資管理(北京)有限公司(以下簡稱“康君投資”)作為普通合夥人設立的寧波康君仲元股權投資合夥企業(有限合夥)(以下簡稱“基金”)。
2021年9月9日,公司收到基金管理人康君投資的通知,該基金已根據《證券投資基金法》和《私募投資基金監督管理暫行辦法》等法律法規的要求在中國證券投資基金業協會完成基金的備案手續,並取得《私募投資基金備案證明》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.